Christopher J.H. Porter

List of Publications by Citations

252 papers	17,616 citations	73 h-index	125 g-index
260 ext. papers	19,367 ext. citations	7.2 avg, IF	6.8 L-index

#	Paper	IF	Citations
252	Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. *Nature Reviews Drug Discovery*, **2007**, 6, 231-48	64.1	1252
251	Strategies to address low drug solubility in discovery and development. *Pharmacological Reviews*, **2013**, 65, 315-499	22.5	992
250	Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. *Advanced Drug Delivery Reviews*, **2008**, 60, 625-37	18.5	581
249	Enhancing intestinal drug solubilisation using lipid-based delivery systems. *Advanced Drug Delivery Reviews*, **2008**, 60, 673-91	18.5	515
248	Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. *Journal of Pharmaceutical Sciences*, **1997**, 86, 269-82	3.9	443
247	From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. *Nature Reviews Drug Discovery*, **2015**, 14, 781-803	64.1	336
246	Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. *Advanced Drug Delivery Reviews*, **2008**, 60, 702-16	18.5	302
245	Minimum information reporting in bio-nano experimental literature. *Nature Nanotechnology*, **2018**, 13, 777-785	28.7	297
244	In vitro assessment of oral lipid based formulations. *Advanced Drug Delivery Reviews*, **2001**, 50 Suppl 1, S127-47	18.5	292
243	Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. *International Journal of Pharmaceutics*, **1998**, 167, 155-164	6.5	277
242	Intestinal lymphatic drug transport: an update. *Advanced Drug Delivery Reviews*, **2001**, 50, 61-80	18.5	276
241	Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. *Journal of Drug Targeting*, **2010**, 18, 704-31	5.4	242
240	Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. *Journal of Pharmacy and Pharmacology*, **2002**, 54, 29-41	4.8	231
239	50years of oral lipid-based formulations: Provenance, progress and future perspectives. *Advanced Drug Delivery Reviews*, **2016**, 101, 167-194	18.5	229
238	Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. *Journal of Pharmaceutical Sciences*, **2000**, 89, 1073-84	3.9	214
237	Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. *Pharmaceutical Research*, **2004**, 21, 1405-12	4.5	197
236	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. *Journal of Pharmaceutical Sciences*, **2012**, 101, 3360-80	3.9	185

235	Lymphatic transport of proteins after subcutaneous administration. *Journal of Pharmaceutical Sciences*, **2000**, 89, 297-310	3.9	182
234	Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. *Journal of Pharmaceutical Sciences*, **2004**, 93, 1110-21	3.9	179
233	Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. *Pharmaceutical Research*, **2004**, 21, 245-53	4.5	160
232	Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. *Journal of Pharmaceutical Sciences*, **2003**, 92, 634-48	3.9	158
231	The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. *Molecular Pharmaceutics*, **2008**, 5, 449-63	5.6	151
230	Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. *Journal of Controlled Release*, **2011**, 153, 180-6	11.7	147
229	Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. *Journal of Pharmaceutical and Biomedical Analysis*, **2001**, 25, 651-61	3.5	146
228	Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. *Nanomedicine*, **2011**, 6, 1063-84	5.6	145
227	An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. *AAPS PharmSci*, **2002**, 4, E40		143
226	Subcutaneous drug delivery and the role of the lymphatics. *Drug Discovery Today: Technologies*, **2005**, 2, 89-96	7.1	141
225	A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. *International Journal of Pharmaceutics*, **2007**, 340, 52-60	6.5	140
224	N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. *PLoS Medicine*, **2007**, 4, e335	11.6	137
223	The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. *FEBS Letters*, **1992**, 305, 62-6	3.8	136
222	Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. *Molecular Pharmaceutics*, **2006**, 3, 614-27	5.6	134
221	Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. *Journal of Pharmaceutical Sciences*, **2008**, 97, 995-1012	3.9	133
220	A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2012**, 8, 103-11	6	132
219	Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. *Journal of Controlled Release*, **2014**, 183, 18-26	11.7	130
218	Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. *Pharmaceutical Research*, **2007**, 24, 748-57	4.5	125

217	Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. *Molecular Pharmaceutics*, **2009**, 6, 1190-204	5.6	122
216	Structure activity relationship of dendrimer microbicides with dual action antiviral activity. *PLoS ONE*, **2010**, 5, e12309	3.7	120
215	The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*, **2019**, 134, 31-59	5.1	119
214	Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2570-9	5.9	115
213	Size and rigidity of cylindrical polymer brushes dictate long circulating properties in vivo. *ACS Nano*, **2015**, 9, 1294-304	16.7	110
212	Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. *Molecular Pharmaceutics*, **2012**, 9, 355-73	5.6	110
211	PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. *Journal of Controlled Release*, **2009**, 140, 108-16	11.7	110
210	Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. *European Journal of Pharmaceutical Sciences*, **2003**, 20, 91-7	5.1	110
209	Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. *Molecular Pharmaceutics*, **2012**, 9, 2063-79	5.6	109
208	Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. *Journal of Controlled Release*, **2011**, 152, 241-8	11.7	107
207	Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. *Pharmaceutical Research*, **2003**, 20, 1460-5	4.5	106
206	Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. *Journal of Pharmaceutical Sciences*, **1996**, 85, 351-6	3.9	106
205	Uptake of drugs into the intestinal lymphatics after oral administration. *Advanced Drug Delivery Reviews*, **1997**, 25, 71-89	18.5	105
204	Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. *Journal of Pharmaceutical Sciences*, **2004**, 93, 332-48	3.9	105
203	A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. *Journal of Pharmaceutical Sciences*, **1996**, 85, 525-9	3.9	105
202	Lipophilic prodrugs designed for intestinal lymphatic transport. *Advanced Drug Delivery Reviews*, **1996**, 19, 149-169	18.5	102
201	Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations. *Molecular Pharmaceutics*, **2015**, 12, 1980-91	5.6	101
200	Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. *Pharmaceutical Research*, **2004**, 21, 254-60	4.5	98

199	Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. *Molecular Pharmaceutics*, **2012**, 9, 3286-300	5.6	97
198	Ionic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility. *Chemical Communications*, **2014**, 50, 1688-90	5.8	93
197	Computational prediction of formulation strategies for beyond-rule-of-5 compounds. *Advanced Drug Delivery Reviews*, **2016**, 101, 6-21	18.5	92
196	Targeting the lymphatics using dendritic polymers (dendrimers). *Advanced Drug Delivery Reviews*, **2011**, 63, 890-900	18.5	92
195	Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief. *Science Translational Medicine*, **2017**, 9,	17.5	91
194	In vitro digestion testing of lipid-based delivery systems: calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products. *International Journal of Pharmaceutics*, **2013**, 441, 323-33	6.5	91
193	Low dose lipid formulations: effects on gastric emptying and biliary secretion. *Pharmaceutical Research*, **2007**, 24, 2084-96	4.5	85
192	Animal models for the study of intestinal lymphatic drug transport. *Advanced Drug Delivery Reviews* , **2001**, 50, 45-60	18.5	84
191	Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 12309-12314	11.5	83
190	Lipid-based systems for the enhanced delivery of poorly water soluble drugs. *Advanced Drug Delivery Reviews*, **2008**, 60, 615-6	18.5	83
189	A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. *Journal of Pharmaceutical Sciences*, **2001**, 90, 1599-607	3.9	82
188	Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. *Molecular Pharmaceutics*, **2013**, 10, 2986-95	5.6	81
187	Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 306, 925-33	4.7	81
186	Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. *Journal of Pharmaceutical Sciences*, **2005**, 94, 481-92	3.9	81
185	Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. *Pharmaceutical Research*, **2013**, 30, 2976-92	4.5	79
184	Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E7438-E7447	11.5	78
183	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations. *Pharmaceutical Research*, **2013**, 30, 3059-76	4.5	78
182	Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. *Journal of Controlled Release*, **2014**, 193, 241-56	11.7	77

181	Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. *Nature Communications*, **2017**, 8, 69	17.4	75
180	Computational prediction of drug solubility in lipid based formulation excipients. *Pharmaceutical Research*, **2013**, 30, 3225-37	4.5	74
179	A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 305, 151-8	4.7	67
178	Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. *Journal of Pharmaceutical Sciences*, **2000**, 89, 168-77	3.9	67
177	The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. *International Journal of Pharmaceutics*, **2000**, 205, 65-78	6.5	65
176	Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier. *Molecular Pharmaceutics*, **2012**, 9, 2750-60	5.6	64
175	Fatty Acid-Binding Protein 5 Facilitates the Blood-Brain Barrier Transport of Docosahexaenoic Acid. *Molecular Pharmaceutics*, **2015**, 12, 4375-85	5.6	63
174	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. *Journal of Controlled Release*, **2013**, 172, 128-136	11.7	61
173	A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs. *Journal of Controlled Release*, **2004**, 99, 217-29	11.7	60
172	Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. *Molecular Pharmaceutics*, **2012**, 9, 422-32	5.6	59
171	PEGylation of interferon □ improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. *Journal of Controlled Release*, **2013**, 168, 200-8	11.7	58
170	Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. *Molecular Pharmaceutics*, **2013**, 10, 1874-89	5.6	58
169	Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. *Journal of Pharmacy and Pharmacology*, **2006**, 58, 809-20	4.8	58
168	Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. *Journal of Controlled Release*, **2014**, 177, 1-10	11.7	57
167	Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. *Journal of Pharmacy and Pharmacology*, **2010**, 62, 856-865	4.8	57
166	Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. *Journal of Pharmaceutical Sciences*, **1996**, 85, 357-61	3.9	57
165	Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. *Journal of Pharmaceutical Sciences*, **2011**, 100, 5069-77	3.9	56
164	Characterization of the drug binding specificity of rat liver fatty acid binding protein. *Journal of Medicinal Chemistry*, **2008**, 51, 3755-64	8.3	55

163	Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. *Drug Metabolism and Disposition*, **2007**, 35, 2211-7	4	55
162	StealthSlipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. *Journal of Controlled Release*, **2014**, 192, 219-27	11.7	54
161	Capping methotrexate carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. *Molecular Pharmaceutics*, **2011**, 8, 338-49	5.6	53
160	Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. *Pharmaceutical Research*, **2002**, 19, 1354-61	4.5	53
159	Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. *Journal of Pharmaceutical Sciences*, **2000**, 89, 168	3.9	53
158	Tools for Early Prediction of Drug Loading in Lipid-Based Formulations. *Molecular Pharmaceutics*, **2016**, 13, 251-61	5.6	52
157	Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. *Journal of Pharmaceutical Sciences*, **1998**, 87, 936-42	3.9	52
156	Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. *Pharmaceutical Research*, **2001**, 18, 1620-6	4.5	51
155	Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 345-51	4.7	50
154	Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase. *Pharmaceutical Research*, **2015**, 32, 1279-87	4.5	49
153	Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. *Journal of Pharmacy and Pharmacology*, **2004**, 56, 69-77	4.8	48
152	Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. *Molecular Pharmaceutics*, **2007**, 4, 949-61	5.6	47
151	A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations. *Pharmaceutical Research*, **2016**, 33, 970-82	4.5	46
150	Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media. *Journal of Pharmacy and Pharmacology*, **2010**, 62, 844-855	4.8	46
149	Permeability assessment of poorly water-soluble compounds under solubilizing conditions: the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2006**, 95, 2170-85	3.9	46
148	The interaction of lipophilic drugs with intestinal fatty acid-binding protein. *Journal of Biological Chemistry*, **2005**, 280, 17769-76	5.4	46
147	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels. *AAPS Journal*, **2014**, 16, 1344-57	3.7	45
146	Fatty Acid-Binding Protein 5 at the Blood-Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function. *Journal of Neuroscience*, **2016**, 36, 11755-11767	6.6	44

145	Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component analysis. *Molecular Pharmaceutics*, **2013**, 10, 2823-48	5.6	44
144	A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. *Journal of Pharmaceutical and Biomedical Analysis*, **1995**, 13, 265-72	3.5	44
143	Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2007**, 96, 280-93	3.9	42
142	Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats. *Molecular Pharmaceutics*, **2015**, 12, 432-43	5.6	41
141	Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles. *Pharmaceutical Research*, **2013**, 30, 3045-58	4.5	40
140	The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. *Journal of Pharmacy and Pharmacology*, **2001**, 53, 1611-9	4.8	40
139	Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin US2: effect of drug type and formulation composition on in vitro pharmaceutical performance. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1734-46	3.9	39
138	The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 881-91	4.7	39
137	Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5087-95	5.9	38
136	Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. *Journal of Controlled Release*, **2013**, 167, 85-91	11.7	38
135	Bile increases intestinal lymphatic drug transport in the fasted rat. *Pharmaceutical Research*, **2005**, 22, 1863-70	4.5	38
134	Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie - International Edition*, **2016**, 55, 13700-13705	16.4	38
133	Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor In a Ligand-selective Manner. *Journal of Biological Chemistry*, **2015**, 290, 13895-906	5.4	37
132	Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. *Pharmaceutical Research*, **2009**, 26, 1486-95	4.5	37
131	The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. *Molecular Pharmaceutics*, **2014**, 11, 496-504	5.6	36
130	Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. *Journal of Pharmaceutical Sciences*, **2014**, 103, 2441-55	3.9	36
129	The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug. *Journal of Pharmaceutical Sciences*, **2013**, 102, 565-78	3.9	36
128	Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?. *Molecular Pharmaceutics*, **2010**, 7, 2297-309	5.6	36

127	Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies. *Molecular Pharmaceutics*, **2017**, 14, 3669-3683	5.6	35
126	Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. *Drug Metabolism and Disposition*, **2003**, 31, 1151-60	4	35
125	Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. *Journal of Receptor and Signal Transduction Research*, **2001**, 21, 215-57	2.6	35
124	Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption. *Pharmaceutical Research*, **2018**, 35, 55	4.5	34
123	Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution. *Biomaterials*, **2018**, 178, 570-582	15.6	34
122	Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components. *Molecular Pharmaceutics*, **2014**, 11, 2825-34	5.6	34
121	The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs. *Molecular Pharmaceutics*, **2013**, 10, 2601-15	5.6	33
120	In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine. *European Journal of Pharmaceutical Sciences*, **2013**, 49, 748-60	5.1	32
119	An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. *Drug Metabolism and Disposition*, **2006**, 34, 729-33	4	32
118	The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. *Pharmaceutical Research*, **2006**, 23, 2060-6	4.5	32
117	Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 1085-92	4.7	32
116	Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. *Pharmaceutical Research*, **2003**, 20, 1156-62	4.5	32
115	The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). *Pharmaceutical Research*, **2010**, 27, 878-93	4.5	31
114	The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. *Pharmaceutical Research*, **2010**, 27, 1949-64	4.5	31
113	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. *Advanced Drug Delivery Reviews*, **2021**, 171, 289-331	18.5	30
112	Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. *Molecular Pharmaceutics*, **2018**, 15, 4568-4576	5.6	29
111	A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport. *Pharmaceutical Research*, **2013**, 30, 3254-70	4.5	28
110	PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. *Molecular Pharmaceutics*, **2015**, 12, 794-809	5.6	28

109	Examination of the role of intestinal fatty acid-binding protein in drug absorption using a parallel artificial membrane permeability assay. *Chemistry and Biology*, **2007**, 14, 453-65		28
108	Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs. *Molecular Pharmaceutics*, **2016**, 13, 3351-3361	5.6	28
107	Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation. *Molecular Pharmaceutics*, **2018**, 15, 2355-2371	5.6	27
106	A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. *Journal of Pharmaceutical Sciences*, **2002**, 91, 647-59	3.9	27
105	Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms. *Advanced Drug Delivery Reviews*, **2019**, 142, 75-90	18.5	26
104	Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases. *Molecular Pharmaceutics*, **2015**, 12, 4424-33	5.6	26
103	Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration. *Drug Delivery and Translational Research*, **2011**, 1, 429-38	6.2	26
102	An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations. *Molecular Pharmaceutics*, **2014**, 11, 4069-83	5.6	25
101	Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion. *Molecular Pharmaceutics*, **2017**, 14, 580-592	5.6	24
100	Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug. *Pharmaceutical Research*, **2015**, 32, 1830-44	4.5	24
99	Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency. *Nano Letters*, **2019**, 19, 1827-1831	11.5	24
98	Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. *Molecular Pharmaceutics*, **2018**, 15, 5678-5696	5.6	24
97	Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids. *Molecular Pharmaceutics*, **2017**, 14, 566-579	5.6	23
96	Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations. *Journal of Pharmaceutical Sciences*, **2018**, 107, 203-216	3.9	23
95	Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations. *Molecular Pharmaceutics*, **2018**, 15, 4733-4744	5.6	23
94	The impact of lymphatic transport on the systemic disposition of lipophilic drugs. *Journal of Pharmaceutical Sciences*, **2013**, 102, 2395-408	3.9	23
93	Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs. *International Journal of Pharmaceutics*, **1996**, 141, 227-237	6.5	23
92	Conjugation of 10 kDa Linear PEG onto Trastuzumab FabSIs Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. *Molecular Pharmaceutics*, **2016**, 13, 1229-41	5.6	22

91	Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. *European Journal of Pharmaceutics and Biopharmaceutics*, **2017**, 119, 408-418	5.7	22
90	Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids. *Molecular Pharmaceutics*, **2017**, 14, 3684-3697	5.6	22
89	Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. *Journal of Pharmaceutical Sciences*, **1998**, 87, 1538-41	3.9	21
88	Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts. *Chemical Communications*, **2016**, 52, 9121-4	5.8	21
87	A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. *Pharmaceutical Research*, **2016**, 33, 510-25	4.5	20
86	Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. *Journal of Pharmaceutical Sciences*, **1999**, 88, 378-84	3.9	20
85	Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. *Molecular Pharmaceutics*, **2016**, 13, 1904-14	5.6	20
84	Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery. *ACS Applied Materials & Interfaces*, **2018**, 10, 31019-31031	9.5	20
83	Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. *Journal of Pharmaceutical Sciences*, **1999**, 88, 185-90	3.9	19
82	A simple quantitative approach for the determination of long and medium chain lipids in bio-relevant matrices by high performance liquid chromatography with refractive index detection. *AAPS PharmSciTech*, **2013**, 14, 927-34	3.9	17
81	The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport. *Journal of Visualized Experiments*, **2015**,	1.6	17
80	Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 331, 700-9	4.7	17
79	Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products. *Journal of Pharmaceutical Sciences*, **2003**, 92, 1262-71	3.9	17
78	Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. *Nature Metabolism*, **2021**, 3, 1175-1188	14.6	17
77	Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2017**, 13, 2485-2494	6	16
76	Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. *Molecular and Cellular Biochemistry*, **2009**, 326, 87-95	4.2	16
75	Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution. *ACS Applied Materials & Interfaces*, **2017**, 9, 33683-33694	9.5	15
74	Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2015**, 11, 2099-108	6	15

73	The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. *Journal of Pharmaceutical Sciences*, **2016**, 105, 293-300	3.9	15
72	Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties. *Molecular Pharmaceutics*, **2019**, 16, 4987-4999	5.6	15
71	A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL. *Journal of Pharmaceutical Sciences*, **2019**, 108, 193-204	3.9	15
70	Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans. *Frontiers in Physiology*, **2020**, 11, 458	4.6	14
69	Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1050-63	3.9	14
68	Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration. *Journal of Pharmaceutical Sciences*, **2015**, 104, 1421-30	3.9	14
67	Probing the fibrate binding specificity of rat liver fatty acid binding protein. *Journal of Medicinal Chemistry*, **2009**, 52, 5344-55	8.3	14
66	Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. *Journal of Controlled Release*, **2005**, 107, 523-36	11.7	14
65	Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. *Pharmaceutics*, **2019**, 12,	6.4	14
64	Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods. *Molecular Pharmaceutics*, **2017**, 14, 394-405	5.6	13
63	Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug. *Journal of Pharmaceutical Sciences*, **2016**, 105, 786-796	3.9	13
62	Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein. *ACS Chemical Biology*, **2014**, 9, 2526-34	4.9	13
61	Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. *Current Drug Delivery*, **2009**, 6, 359-66	3.2	13
60	Targeting immune cells within lymph nodes. *Nature Nanotechnology*, **2020**, 15, 423-425	28.7	12
59	Spatial Properties of Reactive Oxygen Species Govern Pathogen-Specific Immune System Responses. *Antioxidants and Redox Signaling*, **2020**, 32, 982-992	8.4	12
58	Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells. *Journal of Pharmaceutical Sciences*, **2018**, 107, 1185-1193	3.9	12
57	In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 88, 973-85	5.7	12
56	An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. *Biomacromolecules*, **2017**, 18, 2866-2875	6.9	12

55	Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623. *Molecular Pharmaceutics*, **2017**, 14, 4525-4538	5.6	12
54	Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies. *Journal of Pharmaceutical Sciences*, **2012**, 101, 3540-6	3.9	12
53	An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. *Journal of Pharmacy and Pharmacology*, **2010**, 60, 1311-1319	4.8	12
52	Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets. *Journal of Neurochemistry*, **2018**, 144, 81-92	6	12
51	Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. *Journal of Pharmaceutical Sciences*, **2018**, 107, 2509-2513	3.9	11
50	Engineering Biocoatings To Prolong Drug Release from Supraparticles. *Biomacromolecules*, **2019**, 20, 3425-3434	6.9	11
49	Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?. *Pharmaceutical Research*, **2011**, 28, 2176-90	4.5	11
48	Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. *Journal of Pharmaceutical Sciences*, **2008**, 97, 209-24	3.9	11
47	An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli. *Protein Expression and Purification*, **2005**, 44, 23-31	2	11
46	Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo. *Journal of Cardiovascular Pharmacology*, **2003**, 41, 406-13	3.1	11
45	Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation. *Journal of Controlled Release*, **2019**, 296, 29-39	11.7	10
44	Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats. *Journal of Pharmaceutical Sciences*, **2013**, 102, 3957-65	3.9	9
43	Tissue uptake of DDT is independent of chylomicron metabolism. *Archives of Toxicology*, **2006**, 80, 196-200	3.8	9
42	Synthesis and evaluation of 5? alkyl ester prodrugs of zidovudine for directed lymphatic delivery. *International Journal of Pharmaceutics*, **1996**, 144, 61-70	6.5	9
41	Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. *Pharmaceutical Research*, **2015**, 32, 3432-46	4.5	8
40	Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion. *Pharmaceutical Research*, **2014**, 31, 1536-52	4.5	8
39	An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. *Journal of Pharmacy and Pharmacology*, **2008**, 60, 1311-9	4.8	8
38	Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. *Pharmaceutical Research*, **2016**, 33, 2920-2929	4.5	8

37	A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor agonists. *Journal of Biological Chemistry*, **2019**, 294, 3720-3734	5.4	7
36	A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 137, 218-226	5.7	7
35	Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition. *American Journal of Physiology - Renal Physiology*, **2020**, 318, G725-G735	5.1	7
34	An acute and coincident increase in FABP expression and lymphatic lipid and drug transport occurs during intestinal infusion of lipid-based drug formulations to rats. *Pharmaceutical Research*, **2006**, 23, 1786-96	4.5	7
33	Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. *Advanced Drug Delivery Reviews*, **2020**, 160, 115-135	18.5	7
32	Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations. *Pharmaceutical Research*, **2020**, 37, 47	4.5	6
31	Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols. *European Journal of Lipid Science and Technology*, **2006**, 108, 714-722	3	6
30	Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. *Journal of Controlled Release*, **2004**, 95, 275-89	11.7	6
29	Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. *Journal of Controlled Release*, **2021**, 332, 636-651	11.7	6
28	The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. *Journal of Pharmaceutical Sciences*, **2021**, 110, 489-499	3.9	6
27	API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility.. *RSC Advances*, **2020**, 10, 12788-12799	3.7	5
26	Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels. *Journal of Neurochemistry*, **2018**, 146, 186-197	6	5
25	Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. *Journal of Controlled Release*, **2019**, 315, 85-96	11.7	5
24	Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **1997**, 16, 175-80	3.5	5
23	Lymphatic Absorption of Orally Administered Prodrugs **2007**, 653-682		5
22	High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration. *Molecular Pharmaceutics*, **2020**, 17, 2938-2951	5.6	4
21	The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol. *Journal of Pharmacy and Pharmacology*, **2014**, 66, 1377-87	4.8	4
20	Correction to "targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?". *Molecular Pharmaceutics*, **2011**, 8, 2484	5.6	4

19	Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption. *Molecular Pharmaceutics*, **2011**, 8, 1132-9	5.6	4
18	Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?. *Biopharmaceutics and Drug Disposition*, **2003**, 24, 153-7	1.7	4
17	Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 291-5		3
16	Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. *Pharmaceutical Research*, **2021**, 38, 1125-1137	4.5	3
15	Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie*, **2016**, 128, 13904-13909	3.6	3
14	A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes. *Journal of Biological Chemistry*, **2021**, 296, 100345	5.4	3
13	Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. *Nanomedicine*, **2021**, 16, 275-292	5.6	3
12	Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability. *Molecular Pharmaceutics*, **2021**, 18, 1768-1778	5.6	2
11	Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat. *International Journal of Pharmaceutics*, **2021**, 596, 120247	6.5	2
10	Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass Cytometry. *ACS Applied Materials & Interfaces*, **2021**, 13, 35494-35505	9.5	2
9	Frontispiece: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. *Angewandte Chemie - International Edition*, **2016**, 55,	16.4	1
8	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.. *Journal of Controlled Release*, **2021**, 341, 676-701	11.7	1
7	Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation. *European Journal of Pharmaceutics and Biopharmaceutics*, **2021**,	5.7	1
6	Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs. *Journal of Controlled Release*, **2021**, 331, 45-61	11.7	1
5	Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations. *International Journal of Pharmaceutics*, **2021**, 597, 120292	6.5	1
4	Dendrimers for Biomedical Applications. *Frontiers in Nanobiomedical Research*, **2014**, 279-328		
3	Lipid-based Systems, Drug Exposure and Lead Optimization **2006**, 131-150		
2	Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations. *Pharmaceutical Research*, **2021**, 38, 1531-1547	4.5	

1	Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport.. *Frontiers in Pharmacology*, **2022**, 13, 879660	5.6